Abstract
Several diagnostic biomarkers are currently available for clinical use in early-onset cognitive impairment. The decision on which biomarker is used in each patient depends on several factors such as its predictive value or tolerability. There were a total of 40 subjects with early-onset cognitive complaints (<65 years of age): 26 with Alzheimer's disease (AD), five with frontotemporal dementia and nine with diagnostic suspicion of non-neurodegenerative disorder. Clinical and neuropsychological evaluation, lumbar puncture for cerebrospinal fluid (CSF) AD core biochemical marker determination, medial temporal atrophy evaluation on magnetic resonance imaging, amyloid-positron emission tomography (PET) and 18 F-fluorodeoxyglucose-PET were performed. Neurologists provided pre- and post-biomarker diagnosis, together with diagnostic confidence and clinical/therapeutic management. Patients scored the tolerability of each procedure. Cerebrospinal fluid biomarkers and amyloid-PET increased diagnostic confidence in AD (77.4%-86.2% after CSF, 92.4% after amyloid-PET, P < 0.01) and non-neurodegenerative conditions (53.6%-75% after CSF, 95% after amyloid-PET, P < 0.05). Biomarker results led to diagnostic (32.5%) and treatment (32.5%) change...Continue Reading
References
Oct 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·P ScheltensJ Valk
Apr 6, 2007·International Journal of Psychiatry in Medicine·Mario F Mendez
Feb 18, 2011·Neurology·M L Gorno-TempiniM Grossman
Apr 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Marilyn S AlbertCreighton H Phelps
Apr 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Guy M McKhannCreighton H Phelps
May 18, 2011·Neurology·M BalasaUNKNOWN Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group
Aug 4, 2011·Brain : a Journal of Neurology·Katya RascovskyBruce L Miller
Jul 31, 2013·Neurology·Giovanni B FrisoniUNKNOWN ISTAART's NeuroImaging Professional Interest Area
Oct 29, 2013·Journal of Neurology·François Mouton-LigerClaire Paquet
Dec 18, 2013·Journal of Internal Medicine·L A van de Pol, P Scheltens
Mar 1, 2014·Journal of Alzheimer's Disease : JAD·Mircea BalasaAlbert Lladó
Aug 27, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Flora H DuitsWiesje M van der Flier
Nov 14, 2014·Journal of Alzheimer's Disease : JAD·Jeffrey L SeeburgerA David Smith
Sep 1, 2015·European Radiology·Martijn V VerhagenKees Kalisvaart
Oct 17, 2015·Dementia and Geriatric Cognitive Disorders·Welmoed A KrudopYolande A L Pijnenburg
Oct 22, 2016·Journal of Alzheimer's Disease : JAD·Philip S J WestonJonathan M Schott
Sep 18, 2016·Clinical Radiology·H MotaraF U Chowdhury
Feb 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Arno de WildeWiesje M van der Flier
Jun 9, 2017·Neurology·Ian G McKeithKenji Kosaka
Jul 20, 2017·Lancet Neurology·Giovanni B FrisoniBengt Winblad
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Marleen KunnemanEllen M A Smets
Jun 12, 2018·JAMA Neurology·Arno de WildePhilip Scheltens
Citations
Jul 4, 2019·Journal of Neurology·Daniele AltomareUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 17, 2020·Human Brain Mapping·Neus FalgàsRaquel Sánchez-Valle
Jan 21, 2020·Journal of Alzheimer's Disease : JAD·Neus FalgàsAlbert Lladó
Aug 18, 2020·Neuropsychiatric Disease and Treatment·Koung Mi KangUNKNOWN KBASE Research Group
Sep 10, 2019·Frontiers in Neuroscience·Nick BergauAlexander Navarrete Santos
Feb 4, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Mélanie BrissonJean-Paul Soucy
May 25, 2021·Journal of Alzheimer's Disease : JAD·Chenhui MaoJing Gao
Sep 3, 2021·NeuroImage. Clinical·José ContadorUNKNOWN Alzheimer's Disease Neuroimaging Initiative